Patents by Inventor Andrew Peter Moses

Andrew Peter Moses has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems and methods for creating custom actions
    Patent number: 11983484
    Abstract: Disclosed are methods, apparatus, systems, and computer readable storage media for interacting with one or more data objects in an online social network. A user interface includes a publisher with a custom action. The custom action is defined in accordance with custom action instructions provided by a first entity via an application programming interface (API). Such custom action instructions may declaratively or programmatically define the data object, the interaction to be performed with the data object, and other attributes associated with the custom action. A user may request to interact with the data object via selection of the custom action by a second entity. Information may be submitted through the publisher to interact with the data object to update a database system associated with the data object. A feed item may be presented for inclusion in the information feed based on the update.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: May 14, 2024
    Assignee: Salesforce, Inc.
    Inventors: Scott D. Beechuk, Steven Tamm, Orjan N. Kjellberg, Arvind Krishnan, Benjamin Snyder, Luke A. Ball, Shannon Hale, Khanh Kim P. Nguyen, William Gradin, Anna Bonner Mieritz, Beril Guvendik Maples, Gregg Johnson, Andrew Waite, Evan Michael Moses, Weiping Peng, Scott Peter Perket
  • Imidazolidine carboxamide derivatives as P2X7 modulators
    Patent number: 7932282
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: April 26, 2011
    Assignee: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Imidazolidine Carboxamide Derivatives as P2X7 Modulators
    Publication number: 20100075968
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Application
    Filed: April 2, 2008
    Publication date: March 25, 2010
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter